moneyheap
AVNT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Avient Corporation (AVNT) stock moving?
Avient beat Q3 2026 estimates on adjusted EPS ($0.86 vs $0.80) and sales ($891M vs $857M), with organic sales up 10.6% and adjusted EBITDA margin up 80 bps to 17.3%. Full-year adjusted EPS guidance was raised to $3.22–$3.32 from $3.10–$3.25, above the $3.20 consensus, and the company repaid $50M of debt in Q3 and expects to end 2026 at 2.2x–2.3x net debt/adjusted EBITDA. It also made its first buyback since 2022 after quarter end. Three analysts lifted price targets within a week: Truist to $56 (Buy), Wells Fargo to $55 (Overweight), and Barclays to $50 (Equal-Weight). Price jumped from a $43.25 close on Nov 3 to $47.86 on Nov 4 on volume of 1.78M, about double recent averages. It then gave back ground on heavier volume on Nov 5 (close $45.32) and has since held in a $45–46 range, closing at $45.73 on Nov 10 on lower volume of 585K. That leaves the stock about 6% above its pre-earnings close while still below the post-earnings high. The Oct 9 CEO change to Mike Frank, with guidance reaffirmed at that time, adds some leadership-transition risk, and the AI R&D partnership on Nov 9 is a smaller, longer-term item.
News behind the analysis
- Avient Corporation Reports Third Quarter 2026 Financial Results and Raises Full-Year GuidanceQ3 revenue of $891 million and adjusted EPS of $0.86, with full-year adjusted EPS guidance raised to $3.22–$3.32.
- Avient Q3 Adj. EPS $0.86 Beats $0.80 Estimate, Sales $891.200M Beat $857.000M EstimateAdjusted EPS and sales both topped consensus. Q3 organic sales rose 10.6% and adjusted EBITDA margin reached 17.3%, up 80 bps.
- Avient Raises FY2026 Adj EPS Guidance from $3.10-$3.25 to $3.22-$3.32 vs $3.20 EstFull-year adjusted EPS guidance moved above the prior range and consensus. Adjusted EBITDA guidance was narrowed to $593M–$603M.
- Avient Repurchased 281K Shares For About $10.9M After Quarter End, First Buyback Since 2022The company bought back shares after the quarter closed, its first repurchase since 2022. Q3 also saw $50M of debt repaid, $100M year to date.
- Avient Q3 2026 Earnings Call TranscriptTranscript of the third-quarter 2026 earnings call, held the day results were released. Net debt/adjusted EBITDA is expected to end 2026 at 2.2x–2.3x.
- Truist Securities Maintains Avient at Buy, Raises Price Target to $56Truist reaffirmed its Buy rating and raised its price target from $50 to $56.
- Barclays Maintains Avient at Equal-Weight, Raises Price Target to $50Barclays kept its Equal-Weight rating and raised its price target from $44 to $50.
- Wells Fargo Raises Avient Price Target to $55Wells Fargo kept its Overweight rating and raised its price target from $48 to $55.
- Avient Collaborates with Albert Invent to Deploy AI in R&DAvient is integrating AI-powered tools from Albert Invent into its global R&D operations to speed material innovation.
About Avient Corporation
Avient is a Cleveland-based company that makes specialty polymer materials: colorants, additives and inks that it blends into plastics, plus engineered materials such as high-strength composites and Dyneema fiber. Formerly PolyOne, it has remade itself as a specialty materials business. It sells custom formulations to customers in packaging, healthcare, consumer goods, transportation and defense, and had about $3.3 billion in 2025 sales.
How it makes money
Avient sells materials made to customer specifications through two main segments. Color, Additives & Inks (roughly 55–60% of sales) supplies color and performance additives for plastics and fibers. Specialty Engineered Materials (roughly 40–45%) supplies engineered polymers, composites and Dyneema ultra-high-strength fiber, which goes into things like body armor and marine ropes. Because it can usually adjust its prices as raw-material costs change, it can pass much of that inflation on to customers.
What usually moves AVNT
- Industrial and consumer demand, especially in Europe
- Raw-material and resin costs and how well it passes them on in pricing
- Defense and healthcare end-market demand
- Foreign exchange swings
- Debt reduction and share buybacks